2017年KDIGO活体肾脏移植供者评估医疗的临床实践指南解读
|
摘要
<正>肾脏移植是治疗终末期肾病(end stage kidney disease,ESKD)的最佳方式,供肾匮乏是当前移植界面临的最大问题。活体肾移植是解决供肾缺乏的重要手段,同时因其具有移植效果优于尸体肾移植等优势而在全世界广泛开展。活体肾移植是一种特殊类型的医疗实践,是为了挽救别人生命而让一个健康供者接受手术及由此带来的短长期风险。因此,如何最大程度的保障供者利益是医学界和法律界最为关注的问题。为帮助医务工作者评
引文
1Kidney disease:improving global outcomes(KDIGO)living kidney donor work group.KDIGO clinical practice guideline on the evaluation and care of living kidney donors.Transplantation,2017,101(Suppl 8S):S1-S109.
2St Peter WL,Li Q,Liu J,et al.Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization,2004 through 2006.Clin J Am Soc Nephrol,2009,4(2):354-360.
3Segev DL,Gentry SE,Melancon JK,et al.Characterization of waitingtimes in a simulation of kidney paired donation.Am J Transplant,2005,5(10):2448-2455.
4王显丁,邱阳,宋涂润,等.ABO血型不相容亲属活体肾移植的个体化预处理.中华器官移植杂志,2015,36(8):449-452.
5Orandi BJ,Luo X,Massie AB,et al.Survival benefit with kidney transplantsfrom HLA-incompatible live donors.N Engl J Med,2016,374(10):940-950.
6Kidney Disease:Improving Global Outcomes(KDIGO)CKD Work Group.KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int,2013,3(1):1-150.
7Kasiske BL,Anderson-Haag T,Israni AK,et al.A prospective controlled study of living kidney donors:three-year follow-up.Am J Kidney Dis,2015,66(1):114-124.
8Poggio ED,Braun WE,Davis C.The science of stewardship:due diligence for kidney donors and kidney function in living kidney donation—evaluation,determinants,and implications for outcomes.Clin J Am Soc Nephrol,2009,4(10):1677-1684.
9Segev DL,Muzaale AD,Caffo BS,et al.Perioperative mortality and longterm survival following live kidney donation.JAMA,2010,303(10):959-966.
10Len O,Garzoni C,Lumbreras C,et al.Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor-derived infections.Clin Microbiol Infect,2014,20(Suppl 7):10-18.
11European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016.J Hepatol,2017,66(1):153-194.
12U.S.Federal Register.Human Immunodeficiency Virus(HIV)Organ Policy Equity(HOPE)Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV.A Notice by the National Institutes of Health on 06/18/2015.Available at:https://www.federalregister.gov/articles/2015/06/18/2015-15034/human-immunodeficiency-virushiv-organ-policy-equityhope-act-safeguards-and-research-criteria-for.
13Aguado JM,Torre-Cisneros J,Fortún J,et al.Tuberculosis in solidorgan transplant recipients:consensus statement of the group for the study of infection in transplant recipients(GESITRA)of the Spanish Society of Infectious Diseases and Clinical Microbiology.Clin Infect Dis,2009,48(9):1276-1284.
14Nalesnik MA,Woodle ES,Dimaio JM,et al.Donortransmittedmalignancies in organ transplantation:assessment of clinical risk.Am J Transplant,2011,11(6):1140-1147.
15Kanaan N,Devuyst O,Pirson Y.Renal transplantation in autosomal dominant polycystic kidney disease.Nat Rev Nephrol,2014,10(8):455-465.
16Garg AX,Nevis IF,Mc Arthur E,et al.Gestational hypertension and preeclampsia in living kidney donors.N Engl J Med,2015,372(2):124-133.
17Janki S,Verver D,Klop KW,et al.Vascular management during live donor nephrectomy:an online survey among transplant surgeons.Am J Transplant,2015,15(6):1701-1707.
18Manyalich M,Ricart A,Martinez I,et al.EULID project:European living donation and public health.Transplant Proc,2009,41(6):2021-2024.
19Manyalich M,Menjivar A,Yucetin L,et al.Living donor psychosocial assessment/follow-up practices in the partners'countries of the ELIPSY project.Transplant Proc,2012,44(7):2246-2249.
20Scientific Registry of Transplant Recipients.The Living Donor Collective:SRTR to Launch a Pilot Project to Create a Registry of Living Donors.Available at:https://www.srtr.org/newsmedia/news/news-items/news/.
2St Peter WL,Li Q,Liu J,et al.Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization,2004 through 2006.Clin J Am Soc Nephrol,2009,4(2):354-360.
3Segev DL,Gentry SE,Melancon JK,et al.Characterization of waitingtimes in a simulation of kidney paired donation.Am J Transplant,2005,5(10):2448-2455.
4王显丁,邱阳,宋涂润,等.ABO血型不相容亲属活体肾移植的个体化预处理.中华器官移植杂志,2015,36(8):449-452.
5Orandi BJ,Luo X,Massie AB,et al.Survival benefit with kidney transplantsfrom HLA-incompatible live donors.N Engl J Med,2016,374(10):940-950.
6Kidney Disease:Improving Global Outcomes(KDIGO)CKD Work Group.KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int,2013,3(1):1-150.
7Kasiske BL,Anderson-Haag T,Israni AK,et al.A prospective controlled study of living kidney donors:three-year follow-up.Am J Kidney Dis,2015,66(1):114-124.
8Poggio ED,Braun WE,Davis C.The science of stewardship:due diligence for kidney donors and kidney function in living kidney donation—evaluation,determinants,and implications for outcomes.Clin J Am Soc Nephrol,2009,4(10):1677-1684.
9Segev DL,Muzaale AD,Caffo BS,et al.Perioperative mortality and longterm survival following live kidney donation.JAMA,2010,303(10):959-966.
10Len O,Garzoni C,Lumbreras C,et al.Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor-derived infections.Clin Microbiol Infect,2014,20(Suppl 7):10-18.
11European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016.J Hepatol,2017,66(1):153-194.
12U.S.Federal Register.Human Immunodeficiency Virus(HIV)Organ Policy Equity(HOPE)Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV.A Notice by the National Institutes of Health on 06/18/2015.Available at:https://www.federalregister.gov/articles/2015/06/18/2015-15034/human-immunodeficiency-virushiv-organ-policy-equityhope-act-safeguards-and-research-criteria-for.
13Aguado JM,Torre-Cisneros J,Fortún J,et al.Tuberculosis in solidorgan transplant recipients:consensus statement of the group for the study of infection in transplant recipients(GESITRA)of the Spanish Society of Infectious Diseases and Clinical Microbiology.Clin Infect Dis,2009,48(9):1276-1284.
14Nalesnik MA,Woodle ES,Dimaio JM,et al.Donortransmittedmalignancies in organ transplantation:assessment of clinical risk.Am J Transplant,2011,11(6):1140-1147.
15Kanaan N,Devuyst O,Pirson Y.Renal transplantation in autosomal dominant polycystic kidney disease.Nat Rev Nephrol,2014,10(8):455-465.
16Garg AX,Nevis IF,Mc Arthur E,et al.Gestational hypertension and preeclampsia in living kidney donors.N Engl J Med,2015,372(2):124-133.
17Janki S,Verver D,Klop KW,et al.Vascular management during live donor nephrectomy:an online survey among transplant surgeons.Am J Transplant,2015,15(6):1701-1707.
18Manyalich M,Ricart A,Martinez I,et al.EULID project:European living donation and public health.Transplant Proc,2009,41(6):2021-2024.
19Manyalich M,Menjivar A,Yucetin L,et al.Living donor psychosocial assessment/follow-up practices in the partners'countries of the ELIPSY project.Transplant Proc,2012,44(7):2246-2249.
20Scientific Registry of Transplant Recipients.The Living Donor Collective:SRTR to Launch a Pilot Project to Create a Registry of Living Donors.Available at:https://www.srtr.org/newsmedia/news/news-items/news/.